132 results
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
20 Mar 24
RepliCel announces a Letter of Intent for Asset Purchase Agreement
4:38pm
, announces that, on the recommendation of an independent committee (the "Special Committee") of its board of directors (the "Board"), it has entered
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
20 Mar 24
RepliCel announces a Letter of Intent for Asset Purchase Agreement
4:38pm
of an independent committee (the "Special Committee") of its board of directors (the "Board"), it has entered into a non-binding letter of intent ("LOI") dated
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
of the Company have been prepared by and are the responsibility of the Company's management.
The Company's independent auditor has not performed a review
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
of the Company have been prepared by and are the responsibility of the Company's management.
The Company's independent auditor has not performed a review
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Aug 23
Notice of Annual General and Special Meeting of Shareholders
5:15pm
based company which provides independent pharmacies servicing long-term care and home care patients access to cost effective solutions. He … of Advanced Therapies for Blood Centers of America, a cooperative of over 65 independent blood and tissue centers operating over 500 facilities in 43
6-K
EX-99.1
dis6g45f
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
6-K
EX-99.1
ppjpng6
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
20-F/A
wvspfxxj6rdnwefv
12 Sep 22
Annual report (foreign) (amended)
6:17pm
6-K
EX-99.1
b93hvco
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm
UPLOAD
r2ljf yb3h7h
23 Aug 22
Letter from SEC
12:00am
6-K
EX-99.1
1spsyjd8d5rf0vd9 hf
4 Aug 22
Current report (foreign)
11:41am
6-K
EX-99
9bmuqm9 ioskdz0ur
26 Jul 22
Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
1:45pm
6-K
EX-99.3
06t kxlgcwn1j0pudvo
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.1
0wkk9o2k
18 Nov 21
Notice of Annual General and Special Meeting of Shareholders
10:36am
6-K
EX-99.1
rc8g4kzlxagbj
16 Nov 21
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
4:03pm
6-K
EX-99.2
me8j9elc 1hwdxuudvch
16 Nov 21
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
4:03pm
6-K
EX-99.3
9wgd2p6mne
18 Aug 21
RepliCel Life Sciences Announces Closing of Debt Settlement
12:34pm